TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27317162

Group type: EXPERIMENTAL
Intervention: L-carnitine (1000 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 24824813

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic inguinal herniorraphy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multiport laparoscopic inguinal herniorraphy
Number of subjects: 100
Study: 24212170

Group type: EXPERIMENTAL
Intervention: Standard quit smoking counseling program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly intensive quit smoking counseling program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postpartum follow-up session
Number of subjects: 0
Study: 20299499

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (2 courses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (4 courses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (2 courses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (4 courses)
Number of subjects: 60
Study: 19036981

Group type: EXPERIMENTAL
Intervention: 4 mg of the selective NE‐reuptake inhibitor reboxetine (RBX)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30 mg of hydrocortisone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both drugs in combination (RBX and hydrocortisone)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single oral dose of placebo
Number of subjects: 62
Study: 15696567

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone)
Number of subjects: 94
Study: 14618666

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 36
Study: 10807817

Group type: EXPERIMENTAL
Intervention: salbutamol inhalation via pMDI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: salbutamol inhalation via pMDI + spacer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: salbutamol inhalation via Autohaler
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo inhalation
Number of subjects: 18
Study: 8614273

Group type: EXPERIMENTAL
Intervention: ENA 713 12 mg/day bid (n=20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ENA 713 12 mg/day tid (n=20)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ENA 713 (all groups)
Number of subjects: 50
Study: 1991653

Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6140837

Group type: EXPERIMENTAL
Intervention: Live influenza vaccine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3
Study: 31296293

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 192
Study: 29544728

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/10 μg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BGF MDI 80/14.4/10 μg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BGF MDI 160/14.4/10 μg
Number of subjects: 84

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 84
Study: 26423265

Group type: EXPERIMENTAL
Intervention: DPOP-Q
Number of subjects: 109

Group type: COMPARATOR
Intervention: POPstix® POP-Q
Number of subjects: 109
Study: 24925070

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on quadriceps and gastrocnemius 10 min before CPET (20 s/site, 850 nm, 100 mW/diode, 14 J/site)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22504462

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg/h background infusion plus 0.01 mg/kg bolus (BI)
Number of subjects: 86

Group type: COMPARATOR
Intervention: 1.5 mg bolus-only morphine (B0)
Number of subjects: 86
Study: 20480794

Group type: EXPERIMENTAL
Intervention: Onion extract gel (OE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% hydrocortisone, silicone and vitamin E lotion (HSE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17638395

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg once daily
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg once daily + Hydrochlorothiazide 12.5 mg once daily
Number of subjects: 2306

Group type: COMPARATOR
Intervention: Olmesartan medoxomil 20 mg once daily (initial treatment)
Number of subjects: 2306
Study: 16097995

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.d. for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 12
Study: 11871946

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 44
Study: 10464817

Group type: EXPERIMENTAL
Intervention: Methylprednisolone therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: No methylprednisolone therapy (Control)
Number of subjects: 13
Study: 8588120

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg b.i.d.
Number of subjects: 169

Group type: COMPARATOR
Intervention: Ketoprofen 50 mg t.i.d.
Number of subjects: 169
Study: 2110077

Group type: EXPERIMENTAL
Intervention: Aspiration of the leading follicle (group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No aspiration of the leading follicle (group B)
Number of subjects: 12
Study: 7044013

Group type: EXPERIMENTAL
Intervention: Molsidomine (3 x 2 mg/day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31731879

Group type: EXPERIMENTAL
Intervention: SURE test
Number of subjects: 185

Group type: COMPARATOR
Intervention: Decisional Conflict Scale (DCS)
Number of subjects: 185
Study: 29896731

Group type: EXPERIMENTAL
Intervention: Karyotype analysis and BACs-on-Beads (BoBs) assay
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: BACs-on-Beads (BoBs) assay
Number of subjects: 965

Group type: COMPARATOR
Intervention: Karyotype analysis
Number of subjects: 965
Study: 27074374

Group type: EXPERIMENTAL
Intervention: Complementary cognitive-behavioral group sessions (n = 336)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Written information only (n = 350)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Both groups (cognitive-behavioral sessions and written information)
Number of subjects: 686
Study: 24961445

Group type: EXPERIMENTAL
Intervention: Viewing information with attributes in a pre‐specified order (Group 1)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Viewing information with attributes in the order of what mattered most last (Group 2)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Viewing information with attributes in the order of what mattered most first (Group 3)
Number of subjects: 643
Study: 22342506

Group type: EXPERIMENTAL
Intervention: Long agonist half-dose protocol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Short agonist protocol without pretreatment
Number of subjects: 44
Study: 21140955

Group type: EXPERIMENTAL
Intervention: Full item set of twenty CST items
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Standard short version of fourteen items (CST14)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Homogeneous, unidimensional set of selected eleven items
Number of subjects: 466
Study: 17454966

Group type: EXPERIMENTAL
Intervention: Cold pressor test (stressful intervention)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control procedure (non-stressful)
Number of subjects: 64
Study: 16490579

Group type: EXPERIMENTAL
Intervention: IDD-P fenofibrate 160-mg tablet plus atorvastatin 10-mg tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IDD-P fenofibrate 160-mg tablet plus simvastatin 10-mg tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IDD-P fenofibrate 160-mg tablet plus ER niacin 500-mg tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: IDD-P fenofibrate 160-mg tablet alone
Number of subjects: 20
Study: 12582949

Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups during hyperaemia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 20
Study: 11391844

Group type: EXPERIMENTAL
Intervention: MSP (250 mg mefloquine, 500 mg sulphadoxine, and 25 mg pyrimethamine per tablet)
Number of subjects: 4019

Group type: COMPARATOR
Intervention: CQ (150 mg chloroquine base per tablet)
Number of subjects: 4019

Group type: EXPERIMENTAL
Intervention: MSP
Number of subjects: 4019

Group type: COMPARATOR
Intervention: CQ
Number of subjects: 4019
Study: 8637437

Group type: EXPERIMENTAL
Intervention: Subjects with focal frontal epilepsy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subjects with primary generalized epilepsy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 3
Study: 1379523

Group type: EXPERIMENTAL
Intervention: Fazarabine (Ara-AC) at a dose of 2.00 mg m‐2 h‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fazarabine (Ara-AC)
Number of subjects: 0
Study: 6507688

Group type: EXPERIMENTAL
Intervention: Medical self-care education (13-session educational intervention)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Two-hour lecture-demonstration (comparison group)
Number of subjects: 330
Study: 31637991

Group type: EXPERIMENTAL
Intervention: Bipolar disorder with co-morbid PTSD (n = 27)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Bipolar disorder without PTSD
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Conflicting appraisals
Number of subjects: 82
Study: 29617391

Group type: EXPERIMENTAL
Intervention: Biliopancreatic Diversion with Duodenal Switch (BPDS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 28125733

Group type: EXPERIMENTAL
Intervention: Moderate exercise (ModEx; 55%VO2max)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (IntEx; 4 min (80%VO2max)/3 min (50% VO2max))
Number of subjects: 11

Group type: COMPARATOR
Intervention: No exercise (NoEx)
Number of subjects: 11
Study: 26094591

Group type: EXPERIMENTAL
Intervention: HPVOPC patients
Number of subjects: 116

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 116

Group type: COMPARATOR
Intervention: Partners of HPVOPC patients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HPV16 serology
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Younger age and higher oral HPV16 copy number
Number of subjects: 116
Study: 24274358

Group type: EXPERIMENTAL
Intervention: Instaflex™ Joint Support (3 colored gel capsules per day for 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (3 colored gel capsules per day for 8 weeks)
Number of subjects: 100
Study: 21136237

Group type: EXPERIMENTAL
Intervention: Insulin Glargine (GLA)
Number of subjects: 1731

Group type: COMPARATOR
Intervention: Insulin Detemir (DET)
Number of subjects: 1731
Study: 18234045

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg (E40)
Number of subjects: 4312

Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg (E80)
Number of subjects: 4312

Group type: EXPERIMENTAL
Intervention: sumatriptan 100 mg (S100)
Number of subjects: 4312

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4312

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg (E40) and E80
Number of subjects: 4312
Study: 15995003

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei strain ST11 (10^10 CFU daily for 5 days)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 12851564

Group type: EXPERIMENTAL
Intervention: Mime therapy
Number of subjects: 50
Study: 10907666

Group type: EXPERIMENTAL
Intervention: Olanzapine (daily dose: 18.3 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sertindole (daily dose: 16 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Typical antipsychotic drugs (n=12)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Clozapine (n=10)
Number of subjects: 9
Study: 8888661

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5025
Study: 1800390

Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate (3 x 700 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cimetidine (1 x 800 mg/d)
Number of subjects: 48
Study: 6545038

Group type: EXPERIMENTAL
Intervention: Written information explaining the nature of hypertension and the importance of its treatment; advised to see a physician.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group merely advised by letter to see a physician for raised blood pressure.
Number of subjects: 147
Study: 30756280

Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching program (up to 10 calls)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Information only (one call)
Number of subjects: 923
Study: 29247229

Group type: EXPERIMENTAL
Intervention: Follow-up interviews with structured and extended qualitative questions
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Adherence Starts with Knowledge‐12 (ASK‐12) questionnaire
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: COPD and Asthma Sleep Impact Scale (CASIS) questionnaire
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of COPD symptoms
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Self-management strategies for exacerbations (antibiotics, resting, corticosteroids)
Number of subjects: 400
Study: 25866027

Group type: EXPERIMENTAL
Intervention: 4 Gy irradiation with fixation after 24 h (cell recovery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 Gy irradiation with fixation after various time points (double strand break repair kinetics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded single radiation doses with fixation after 24 h (dose-response)
Number of subjects: 0
Study: 24721435

Group type: EXPERIMENTAL
Intervention: High cardiovascular risk management program delivered by village doctors
Number of subjects: 9600

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9600
Study: 21700548

Group type: EXPERIMENTAL
Intervention: HPV(HR) auto-test at home
Number of subjects: 9334

Group type: COMPARATOR
Intervention: Second invitation to Pap test
Number of subjects: 9334

Group type: EXPERIMENTAL
Intervention: HPV(HR) auto-test
Number of subjects: 9334

Group type: COMPARATOR
Intervention: Pap test
Number of subjects: 9334
Study: 18989693

Group type: EXPERIMENTAL
Intervention: beta-alanine (BA)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: high-intensity interval training (HIIT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: control (CON)
Number of subjects: 46
Study: 18167291

Group type: EXPERIMENTAL
Intervention: Modified autologous pericardial monocuspid valve
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional pericardial monocuspid valve patch
Number of subjects: 20
Study: 15451058

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg zinc as gluconate daily for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10770539

Group type: EXPERIMENTAL
Intervention: RCT (randomized controlled trial)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Observational patients
Number of subjects: 160
Study: 9581004

Group type: EXPERIMENTAL
Intervention: Cocaine-specific coping skills training (CST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 0
Study: 8180524

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg i.v. injection followed by 20 mg tablet once daily for 6 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg i.m. injection followed by 50 mg tablet 4 to 6 hours postoperatively and 50 mg three times daily for 6 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tenoxicam (suggested 40 mg dose at induction of anesthesia)
Number of subjects: 25
Study: 3540870

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg at dose 1 and 100 mg at doses 2 and 3
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg at dose 1 and 50 mg at doses 2 and 3
Number of subjects: 168

Group type: COMPARATOR
Intervention: Codeine 60 mg at all three doses
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo at all three doses
Number of subjects: 168
Study: 31674241

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard wound management
Number of subjects: 460
Study: 27311454

Group type: EXPERIMENTAL
Intervention: Community-based care package involving regular telephone contact and three home visits over two years.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care consisting of a telephone call and an optional home visit.
Number of subjects: 30
Study: 26260733

Group type: EXPERIMENTAL
Intervention: Contact Force-sensing catheter
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (non-CF catheter)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Contact Force-sensing catheter (optimal CF)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Contact Force-sensing catheter (nonoptimal CF)
Number of subjects: 300
Study: 23143561

Group type: EXPERIMENTAL
Intervention: Teflon-platinum prostheses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitinol prostheses
Number of subjects: 30
Study: 21724341

Group type: EXPERIMENTAL
Intervention: Weekly marijuana users
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Weekly marijuana smokers
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 236

Group type: COMPARATOR
Intervention: Marijuana users vs non-users
Number of subjects: 236
Study: 19739697

Group type: COMPARATOR
Intervention: Memantine monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memantine plus donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 0
Study: 17440998

Group type: EXPERIMENTAL
Intervention: Saturated diet (SAT) enriched in saturated fatty acid (SFA) (38% fat, 20% SFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mediterranean diet (MEDIT) enriched in monounsaturated fatty acid (MUFA) (38% fat, 22% MUFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (CHO) (30% fat, 55% CHO)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Saturated diet (SAT)
Number of subjects: 59
Study: 15450839

Group type: EXPERIMENTAL
Intervention: High-viscosity 2-octylcyanoacrylate
Number of subjects: 209

Group type: COMPARATOR
Intervention: Commercially available devices
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: New 2-octylcyanoacrylate formulation
Number of subjects: 209

Group type: COMPARATOR
Intervention: Old 2-octylcyanoacrylate formulation
Number of subjects: 209
Study: 11170948

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Vancomycin (1 g intravenously twice daily)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Linezolid and Vancomycin
Number of subjects: 203
Study: 9924006

Group type: COMPARATOR
Intervention: 0 mg Cu/l (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg Cu/l
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg Cu/l
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg Cu/l
Number of subjects: 60
Study: 7584882

Group type: EXPERIMENTAL
Intervention: Orchidectomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Combined oral and intramuscular estrogens
Number of subjects: 27
Study: 2318372

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment consisting of monthly check-ups, home blood pressure measurements, and lifestyle advice (salt restriction, weight reduction, physical activity, reduction of alcohol and tobacco)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment
Number of subjects: 400
Study: 6965324

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (10-minute treatment)
Number of subjects: 21
Study: 31397587

Group type: EXPERIMENTAL
Intervention: Counterstereotypic condition (uncontrollable explanation of obesity)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Stereotypic condition (emphasized lifestyle choices)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control condition (weight not addressed)
Number of subjects: 350
Study: 30640655

Group type: EXPERIMENTAL
Intervention: 20 mL 0.375% ropivacaine (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 30 mL 0.375% ropivacaine (Group B)
Number of subjects: 80
Study: 28494915

Group type: EXPERIMENTAL
Intervention: SLOW group (36 patients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: FAST group (41 patients)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: SLOW group
Number of subjects: 77

Group type: COMPARATOR
Intervention: FAST group
Number of subjects: 77
Study: 26529533

Group type: EXPERIMENTAL
Intervention: Coflex‐F rigid interspinous spacer
Number of subjects: 90

Group type: COMPARATOR
Intervention: 4‐point transpedicular rod fixation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (interbody fusion with Pezo‐T PEEK cage)
Number of subjects: 90
Study: 22727783

Group type: EXPERIMENTAL
Intervention: Pre-treatment craving measured using the Obsessive subscale of the Obsessive Compulsive Drinking Scale
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pre-treatment depressive mood
Number of subjects: 260
Study: 20932667

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) - three cycles of cisplatin-based chemotherapy followed by CHART
Number of subjects: 46

Group type: COMPARATOR
Intervention: CHART alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 46
Study: 19167144

Group type: EXPERIMENTAL
Intervention: Peer-group support intervention combined with monthly somatic healthcare (n=159)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group (n=167)
Number of subjects: 326